Use of prescription proton pump inhibitors (PPIs) within  months prior to study entry\r\n* Dexlansoprazole (Dexilant)\r\n* Pantoprazole (Protonix)\r\n* Rabeprazole (AcipHex)\r\n* Esomeprazole (Nexium)\r\n* Lansoprazole (Prevacid)\r\n* Omeprazole (Prilosec, Zegerid)
A medical condition requiring use of proton pump inhibitors (PPIs); or histamine  (H) receptor antagonists; patients who intermittently use these medications, must meet the following criteria:\r\n* No use of PPIs within  days before the first dose of alisertib\r\n* No use of H antagonist or pancreatic enzymes within  hours before the first dose of alisertib
Proton pump inhibitor: the concomitant use of proton-pump inhibitors (including, but not limited to, dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole) with palbociclib is prohibited; recommendations about the use of antacids or H-receptor antagonists include, but not limited to: cimetidine, famotidine, nizatidine, and ranitidine; if needed, administer H-receptor antagonists with a staggered dosing regimen (twice daily); the dosing of palbociclib should occur at least  hours after H-receptor antagonist evening dose and  hours before the H-receptor antagonist morning dose; local antacids: as acid lowering agents, local antacids may decrease palbociclib absorption and exposure; however, if needed, local antacids should be given at least  hours before or at least  hours after palbociclib administration
Proton-pump inhibitors and histamine H-receptor antagonists;
Treatment with any of the following; histamine receptor  inhibitors, proton pump inhibitors or antacids within  days or  half-lives of administration of BGB, whichever is longer.
Treatment with proton pump inhibitors within  days prior to study entry; if continued use of gastrointestinal (GI) prophylaxis is required, the patient will be switched to an appropriate histamine (H) antagonist with appropriate counsel and caution
Participants who require continuous use of proton pump inhibitors (PPIs) or histamine- (H) receptor antagonists and participants who are taking PPIs within  days before the first dose of study drug.
Treatment with any of the following: histamine receptor  inhibitors, proton pump inhibitors or antacids within  days of start of study treatment.
Use of proton-pump inhibitors within  days prior to the first dose of study drug. Other medications that increase gastric pH, ie, histamine H receptor antagonists and antacids may be taken provided they are not administered within  hours before or after administration of study drug.
Need for ongoing therapy with proton pump inhibitors; H antagonists are allowed
Not receiving administration of proton pump inhibitor, H antagonist, or pancreatic enzymes
No requirement for constant administration of proton pump inhibitor, H antagonist, or pancreatic enzymes
Histamine  (H) antagonists and proton pump inhibitors are not allowed
Requirement for constant administration of proton-pump inhibitor, histamine  (H) antagonist, or pancreatic enzymes; intermittent uses of antacids or H antagonists are allowed while patients are on dexamethasone; we strongly recommend that patients who require gastric protection to receive only antacids starting  hours before the first dose until  hours after the last dose of alisertib
Concomitant use of proton pump inhibitors, H-receptor antagonists, antacids
Concomitant use of acid reducing agents (e.g., proton pump inhibitors, histamine  (H) receptor antagonists, antacids)
The concomitant use of histamine (H) blockers and proton pump inhibitors (PPIs) with dasatinib is not recommended; the use of antacids should be considered in place of H blockers or proton pump inhibitors in patients receiving dasatinib therapy; if antacid therapy is needed, the antacid dose should be administered two hours before or after the dose of dasatinib; patients who cannot tolerate discontinuation of H blockers or PPIs are ineligible
Requirement for constant administration of proton pump inhibitor, H antagonist, or pancreatic enzymes; intermittent uses of antacids or H antagonists are allowed
Patients who have a requirement for constant administration of proton pump inhibitor, histamine- (H) antagonist, or pancreatic enzymes are not eligible; intermittent usage of antacids or H antagonists are allowed
Achlorhydria or use of antacids, proton-pump inhibitors, or other drugs known to raise gastric pH within  weeks before study drug administration.
Requirement for constant administration of proton pump inhibitor, histamine  (H) antagonist, or pancreatic enzymes; intermittent uses of antacids or H antagonists are allowed
The patient requires treatment with a pH elevating agent, including H blockers, proton pump inhibitors, and antacids. If the medication is considered to be medically necessary, the patient should be discussed with the Medical Monitor.
No concurrent administration of cimetidine (as it can decrease the clearance of fluorouracil [-FU]); another histamine- receptor (H)-blocker or proton pump inhibitor may be substituted before study entry
Requirement for constant administration of proton pump inhibitor, histamine (H) antagonist, or pancreatic enzymes; intermittent uses of antacids or H antagonists are allowed as described
Requirement for constant administration of proton pump inhibitor, histamine- (H) antagonist, or pancreatic enzymes; histamine- (H) receptor antagonists are not permitted from the day prior (day -) through to the end of alisertib dosing (e.g., day ), except as required for premedication for a protocol-specific agent (e.g., taxane); neutralizing antacids and calcium-containing supplements cannot be taken from  hours prior to alisertib dosing until up to  hours after dosing
Requirement for constant administration of proton pump inhibitor or H antagonist; intermittent uses of antacids or H antagonists are allowed
Requirement for constant administration of proton pump inhibitors, H antagonists, or pancreatic enzymes; intermittent uses of antacids or H antagonists are allowed
Patients should not be on cimetidine; another histamine- (H)-blocker or proton pump inhibitor may be substituted before study entry
Patient must not require constant administration of a proton pump inhibitor, histamine receptor  (H) antagonist, or pancreatic enzymes; intermittent uses of antacids or H antagonists are allowed
Patients should not be on cimetidine; another histamine  (H)-blocker or proton pump inhibitor may be substituted before study entry
Patients should not be on cimetidine; another histamine  (H)-blocker or proton pump inhibitor may be substituted before study entry
Proton pump inhibitors, such as rabeprazole, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, and pantoprazole are prohibited; short acting antacids such as Maalox Maximum Strength are allowed
Proton pump inhibitors and histamine- (H) inhibitors
Requirement for constant administration of proton pump inhibitor from  days prior to D of alisertib, and/or requirement for constant administration of histone  (H) antagonist, or pancreatic enzymes; intermittent uses of antacids or H antagonists are allowed
Has taken histamine-H receptor antagonists and/or neutralizing antacids within  hours before the first administration of study drug.
Treatment with proton pump inhibitors within  days prior to study entry; if treatment with an histamine (H)-receptor antagonist such as ranitidine is required, erlotinib must be taken  hours after the H-receptor antagonist dosing and at least  hours before the next dose of the H-receptor antagonist; although the effect of antacids on erlotinib pharmacokinetics has not been evaluated, the antacid dose and the erlotinib dose should be separated by several hours, if an antacid is necessary
Concomitant use of proton pump inhibitors or histamine (H) blockers
Concomitant treatment with medicinal products that increase the pH (reduce acidity) of the upper gastrointestinal tract, including, but not limited to, proton-pump inhibitors (e.g. omeprazole), H-antagonists (e.g. ranitidine) and antacids. Patients may be enrolled in the study after a wash-out period sufficient to terminate their effect.
Concomitant treatment with medicinal products that increase the potential hydrogen (pH), reduce acidity of the upper gastrointestinal tract, including, but not limited to, proton-pump inhibitors (e.g. omeprazole), H-antagonists (e.g. ranitidine) and antacids. Patients may be enrolled in the study after a washout period sufficient to terminate their effect.
A medical condition requiring use of pancreatic enzymes; daily, chronic, or regular use of proton pump inhibitors (PPIs); or histamine  (H) receptor antagonists. Participants who intermittently use these medications, must meet the following criteria:
Patients who are on daily proton pump inhibitor therapy must be able to discontinue use or only require use of antacid or hydrogen (H) antagonist intermittently; patients who require daily administration of proton pump inhibitor, H antagonist, or pancreatic enzymes are not eligible; intermittent uses of antacids or H antagonists are allowed
Requirement for constant administration of proton pump inhibitor, H antagonist, or pancreatic enzymes. Intermittent uses of antacids or H antagonists are allowed (see section .)
Requirement for continued proton pump inhibitor after randomization
Requirement for constant administration of proton pump inhibitor, histamine (H) antagonist, or pancreatic enzymes; intermittent uses of antacids or H antagonists are allowed
Receiving histamine type  (H) antagonists (cimetidine, ranitidine, famotidine, nizatidine) or proton pump inhibitors lansoprazole, omeprazole, pantoprazole, esomeprazole, raberprazole, dexlansoprazole) AND unable to hold the drug for  h prior to and  h after each cisplatin course on cycles -
Treatment with any of the following: histamine receptor two inhibitors, protocol pump inhibitors or antacids within three days or five half-lives, whichever is longer
Concurrent use of antacids, hydrogen (H) antagonists, proton-pump inhibitors, or medications known to inhibit or induce hepatic enzyme cytochrome P (CYP) A
For weekly MLN (TAK-) dose cohorts, patients taking proton pump inhibitors (PPIs) are ineligible unless these patients are able to switch to a histamine (H) blocker and/or antacid
Intestinal motility agents, histamine? inverse agonists (H? blockers), or proton pump inhibitors
